| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028561819 |
| P356 | DOI | 10.1007/S00406-009-0033-1 |
| P698 | PubMed publication ID | 19579000 |
| P50 | author | Axel Becker | Q43098345 |
| P2093 | author name string | Gerburg Keilhoff | |
| Hans-Gert Bernstein | |||
| Gisela Grecksch | |||
| Thomas Roskoden | |||
| P2860 | cites work | VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants | Q28579192 |
| Neuroimaging studies of the hippocampus in schizophrenia | Q30666577 | ||
| Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. | Q33210386 | ||
| Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Conne | Q33301092 | ||
| The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 | ||
| Implications of adult hippocampal neurogenesis in antidepressant action. | Q33553686 | ||
| Atypical antipsychotics: mechanism of action. | Q33957716 | ||
| NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia | Q34149624 | ||
| Hippocampal neurons in schizophrenia | Q34383604 | ||
| Hippocampal dysfunction in schizophrenia | Q34456350 | ||
| BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation | Q34571476 | ||
| Neurogenic actions of atypical antipsychotic drugs and therapeutic implications | Q34662630 | ||
| Current status of antipsychotic treatment | Q35137427 | ||
| Nitric oxide negatively regulates mammalian adult neurogenesis | Q35234923 | ||
| p38 MAPK as a negative regulator of VEGF/VEGFR2 signaling pathway in serum deprived human SK-N-SH neuroblastoma cells | Q36477800 | ||
| Targeting the dopamine D2 receptor in schizophrenia | Q36539461 | ||
| Schizophrenia: new pathological insights and therapies | Q36563424 | ||
| Adult neurogenesis and schizophrenia: a window on abnormal early brain development? | Q36661948 | ||
| A model for neuronal competition during development | Q36728766 | ||
| Neurogenesis and schizophrenia: dividing neurons in a divided mind? | Q36806465 | ||
| Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? | Q36860053 | ||
| Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. | Q36890568 | ||
| Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation | Q37068695 | ||
| Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice | Q37468643 | ||
| Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro | Q40158583 | ||
| Cell loss in the hippocampus of schizophrenics | Q41478815 | ||
| Cis-4-methylsphingosine phosphate induces apoptosis in neuroblastoma cells by opposite effects on p38 and ERK mitogen-activated protein kinases | Q42805853 | ||
| ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment | Q43561612 | ||
| Atypical neuroleptics stimulate neurogenesis in adult rat brain | Q44059818 | ||
| Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration | Q44189362 | ||
| Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia | Q44466191 | ||
| Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration | Q44900381 | ||
| Increased neurogenesis in a rat ketamine model of schizophrenia | Q45035940 | ||
| Requirement for neurogenesis to proceed through the division of neuronal progenitors following differentiation of epidermal growth factor and fibroblast growth factor-2-responsive human neural stem cells | Q45041233 | ||
| Temporally specific burst in cell proliferation increases hippocampal neurogenesis in protracted abstinence from alcohol. | Q45128010 | ||
| Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity | Q45180509 | ||
| Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. | Q46549241 | ||
| Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. | Q46785501 | ||
| Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex | Q46888961 | ||
| Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus | Q46989886 | ||
| Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation | Q48102641 | ||
| Modulation of mRNA expression of the neurotrophins of the nerve-growth-factor family and their receptors in the septum and hippocampus of rats after transient postnatal thyroxine treatment. II. Effects on p75 and trk receptor expression | Q48133250 | ||
| Neurogenesis in the adult brain: is there an association with mental disorders? | Q48144058 | ||
| Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. | Q48390432 | ||
| Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus | Q48433223 | ||
| Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics | Q48522635 | ||
| Effects of repeated phencyclidine administration on adult hippocampal neurogenesis in the rat. | Q48593104 | ||
| Neural stem cell proliferation is decreased in schizophrenia, but not in depression. | Q48686220 | ||
| Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. | Q51973672 | ||
| Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia | Q73081300 | ||
| Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration | Q73911873 | ||
| The hippocampus in schizophrenia | Q80930895 | ||
| JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells | Q83283109 | ||
| P433 | issue | 2 | |
| P921 | main subject | haloperidol | Q251347 |
| risperidone | Q412443 | ||
| P304 | page(s) | 151-162 | |
| P577 | publication date | 2009-07-05 | |
| P1433 | published in | European Archives of Psychiatry and Clinical Neuroscience | Q661388 |
| P1476 | title | Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. | |
| P478 | volume | 260 |
| Q43182337 | Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity |
| Q30375799 | Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia |
| Q30395004 | Adult neurogenesis and mental illness |
| Q38734770 | Adult neurogenesis and neurodegenerative diseases: A systems biology perspective |
| Q48711490 | Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics. |
| Q52152130 | Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. |
| Q37845379 | Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes |
| Q35777839 | DISC1-mediated dysregulation of adult hippocampal neurogenesis in rats |
| Q38109214 | Developmental neuroplasticity and the origin of neurodegenerative diseases |
| Q26823735 | Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update |
| Q34615297 | Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions. |
| Q36136017 | Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients |
| Q30455448 | Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice |
| Q96128638 | Haloperidol's Effect on the Expressions of TGFB, NT-3, and BDNF genes in Cultured Rat Microglia |
| Q36790073 | Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder |
| Q50068611 | Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis |
| Q64065882 | NMDA Receptor Model of Antipsychotic Drug-Induced Hypofrontality |
| Q53297745 | Neuroprotection of posttreatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a gerbil model of ischemic stroke. |
| Q48164256 | POU3F2 participates in cognitive function and adult hippocampal neurogenesis via mammalian-characteristic amino acid repeats. |
| Q48783271 | Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis |
| Q30468855 | Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine |
| Q35390344 | Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia |
| Q38482062 | Role of adult hippocampal neurogenesis in cognition in physiology and disease: pharmacological targets and biomarkers |
| Q37914375 | Synapsin III: role in neuronal plasticity and disease |
| Q40299879 | The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease |
| Q43762923 | Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. |
Search more.